quinuclidines has been researched along with netupitant in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (76.67) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pietra, C; Rojas, C; Slusher, BS; Stathis, M | 1 |
| Grunberg, SM; Rugo, HS; Slusher, B | 1 |
| Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W | 1 |
| Calcagnile, S; Giuliano, C; Lanzarotti, C; Mair, S; Nisbet, I; Rossi, G; Spinelli, T; Stevens, L | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Grunberg, S; Karthaus, M; Lorusso, V; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Alyasova, A; Bondarenko, I; Gralla, RJ; Hesketh, PJ; Lisyanskaya, A; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Balser, C; Borroni, ME; Bosnjak, SM; Gralla, RJ; Hontsa, A; Jordan, K; Rizzi, G; Rossi, G | 1 |
| Andrews, PLR | 1 |
| Rojas, C; Slusher, BS; Stathis, M; Thomas, AG | 1 |
| Bee, LA; Dickenson, A; Greenwood-Van Meerveld, B; Mohammadi, E; Pietra, C; Tyler, K | 1 |
| Aapro, M; Karthaus, M; Lorusso, V | 1 |
| Thompson, CA | 1 |
| Navari, RM | 1 |
| Chebolu, S; Darmani, NA; Mercadante, F; Zhong, W | 1 |
| Abramovitz, RB; Gaertner, KM | 1 |
| Calcagnile, S; Cox, D; Kashef, K; Lanzarotti, C; Natale, JJ; Rossi, G; Spinelli, T | 1 |
| Aapro, M; Bosnjak, S; Hesketh, PJ; Jordan, K; Rugo, H; Schwartzberg, L | 1 |
| Chen, H; Du, J; Li, H; Li, S; Li, W; Ni, Y; Xu, M; Zhou, Y | 1 |
| Gralla, R; Jordan, K; Kashef, K; Rizzi, G | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Hansen, V; Karthaus, M; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Bonizzoni, E; Celio, L; Croce, D; Di Turi, R; Nardulli, P; Perrone, T; Restelli, U; Saibene, G; Scolari, F | 1 |
| Celio, L; Fabbroni, C | 1 |
| Badalamenti, G; Bazan, V; Casarin, A; De Luca, I; Incorvaia, L; Messina, C; Musso, E; Ricciardi, MR; Russo, A | 1 |
| Bruera, E; Gallagher, C; Hui, D; Javle, M; Kaseb, A; Liu, D; Maddi, R; Overman, M; Puac, V; Shelal, Z; Yennurajalingam, S | 1 |
| Bertolini, F; Bonizzoni, E; Bria, E; Carnio, S; Cassano, A; Cavanna, L; Celio, L; Chiari, R; Cogoni, AA; Collovà, E; Cortinovis, D; De Placido, S; Gernone, A; Letizia, A; Martelli, O; Misino, A; Petrelli, F; Pilotto, S; Pisconti, S; Vittimberga, I; Zanelli, F | 2 |
| Canale, FA; Console, G; Cusumano, G; Di Costanzo, A; Ferreri, A; Gallo, S; Gangemi, T; Irrera, G; Loddo, V; Loteta, B; Martino, M; Meliambro, N; Moscato, T; Naso, V; Paviglianiti, A; Porcino, D; Porto, G; Provenzano, PF; Pugliese, M; Romeo, V; Rossetti, AM; Russo, L | 1 |
| Abdul Rahman, MHFB; Abdullah, MM; Ahmad Annuar, MA; Ahmad Badruddin, RBA; Chong, KJ; Lai, CNB; Lam, KS; Lau, KL; Low, JSH; Md Yusof, M; Ng, SC; Nonis, JG; Yap, BK | 1 |
| Aapro, M; Eriksson, J; Lezzi, C; Nilsson, J; Piovesana, V; Turini, M | 1 |
| Abe, M; Aogi, K; Iihara, H | 1 |
7 review(s) available for quinuclidines and netupitant
| Article | Year |
|---|---|
Emerging treatments in chemotherapy-induced nausea and vomiting.
Topics: Allosteric Regulation; Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Isoquinolines; Molecular Structure; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2016 |
Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Guideline Adherence; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective.
Topics: Antiemetics; Antineoplastic Agents; Humans; Nausea; Quinuclidines; Vomiting | 2023 |
9 trial(s) available for quinuclidines and netupitant
| Article | Year |
|---|---|
Netupitant PET imaging and ADME studies in humans.
Topics: Adult; Area Under Curve; Bile; Biomarkers; Drug Combinations; Humans; Isoquinolines; Kidney; Liver; Male; Middle Aged; Neurokinin-1 Receptor Antagonists; Palonosetron; Piperidines; Positron-Emission Tomography; Pyridines; Quinuclidines; Radiopharmaceuticals; Serotonin 5-HT3 Receptor Antagonists; Tetrazoles; Tissue Distribution; Young Adult | 2014 |
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Palonosetron; Pyridines; Quinuclidines; Receptors, Neurokinin-1 | 2016 |
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Topics: Adult; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting; Young Adult | 2017 |
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pilot Projects; Pyridines; Quinuclidines; Vomiting | 2021 |
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Humans; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2021 |
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
Topics: Antiemetics; Antineoplastic Agents; Benzeneacetamides; Cisplatin; Dexamethasone; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
14 other study(ies) available for quinuclidines and netupitant
| Article | Year |
|---|---|
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
Topics: Animals; Cell Line, Tumor; Drug Synergism; Isoquinolines; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Serotonin 5-HT3 Receptor Antagonists; Substance P | 2012 |
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Topics: Adolescent; Adult; Antiemetics; Area Under Curve; Contraceptives, Oral; Cross-Over Studies; Drug Interactions; Female; Humans; Isoquinolines; Ketoconazole; Middle Aged; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Rifampin; Young Adult | 2013 |
Netupitant and palonosetron (NEPA): a winning team in the race for the optimal treatment of chemotherapy-induced nausea and vomiting?
Topics: Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.
Topics: Acids; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Administration Schedule; HEK293 Cells; Humans; Isoquinolines; Mice; Neuroblastoma; Neurokinin-1 Receptor Antagonists; Palonosetron; Peptide Hydrolases; Protein Binding; Protein Transport; Pyridines; Quinuclidines; Rats; Receptors, Neurokinin-1; Serotonin Antagonists; Time Factors; Tritium | 2014 |
Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain.
Topics: Action Potentials; Administration, Oral; Animals; Colon; Drug Combinations; Drug Synergism; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Nociceptive Pain; Palonosetron; Posterior Horn Cells; Pyridines; Quinuclidines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Visceral Pain | 2014 |
Netupitant-palonosetron combination approved by FDA.
Topics: Antiemetics; Antineoplastic Agents; Drug Approval; Drug Combinations; Drug Interactions; Drug Labeling; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; United States; United States Food and Drug Administration; Vomiting | 2014 |
Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation.
Topics: Animals; Antiemetics; Cisplatin; Cyclic AMP-Dependent Protein Kinases; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Isoquinolines; Male; Neurokinin-1 Receptor Antagonists; Palonosetron; Protein Kinase C; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Shrews; Vomiting | 2015 |
Development and validation of a rapid LC-MS/MS method for simultaneous determination of netupitant and palonosetron in human plasma and its application to a pharmacokinetic study.
Topics: Antiemetics; Chromatography, High Pressure Liquid; Humans; Isoquinolines; Limit of Detection; Liquid-Liquid Extraction; Palonosetron; Pyridines; Quinuclidines; Serotonin Antagonists; Tandem Mass Spectrometry; Time Factors | 2016 |
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.
Topics: Antiemetics; Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Health Resources; Humans; Isoquinolines; Italy; National Health Programs; Nausea; Palonosetron; Pyridines; Quality of Life; Quality-Adjusted Life Years; Quinuclidines; Vomiting | 2017 |
Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
Topics: Administration, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Nausea; Palonosetron; Pyridines; Quinuclidines; Radiotherapy; Vomiting | 2018 |
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Pilot Projects; Prospective Studies; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2019 |
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Topics: Antiemetics; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Nausea; Palonosetron; Pyridines; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2022 |
Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzeneacetamides; Dexamethasone; Hematologic Neoplasms; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cost-Benefit Analysis; Emetics; Humans; Internationality; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |